(RTTNews) - Evaxion Biotech (EVAX), a clinical-stage TechBio company, announced on Wednesday that it has completed dosing for all 16 patients in its Phase 2 trial of EVX-01, a personalized cancer ...
After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE ...
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results Principal investigator Professor ...
Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights ...
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 ...
COPENHAGEN, Denmark, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results